Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL355576 | 0.87 | HPGD (0.56) | KMT2AMEN1HDAC1HDAC6SMN1; SMN2 | |
| SCHEMBL21962176 | 0.87 | SMN1; SMN2 (0.55) | KMT2AMEN1HDAC1HDAC6SMN1; SMN2 | |
| SCHEMBL16982524 | 0.86 | KMT2A (0.75) | KMT2AMEN1HDAC1HDAC6ALOX15 | |
| SCHEMBL23320281 | 0.84 | MEN1 (0.49) | KMT2AMEN1HDAC1HDAC6SMN1; SMN2 | |
| SCHEMBL1711291 | 0.84 | TSHR (0.65) | KMT2AMEN1SMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL8280049 | 0.83 | PKM (0.57) | KMT2AMEN1KDM4EMAPTTSHR | |
| SCHEMBL1018987 | 0.83 | SIGMAR1 (0.53) | KMT2AMEN1HDAC1HDAC6HSD11B1 | |
| SCHEMBL13451259 | 0.82 | HSD11B1 (0.52) | KMT2AMEN1HDAC1HDAC6HSD11B1 | |
| SCHEMBL1512434 | 0.81 | LRRK2 (0.61) | KMT2AMEN1SMN1; SMN2HSD11B1ALDH1A1 | |
| SCHEMBL1512564 | 0.81 | MEN1 (0.67) | KMT2AMEN1SMN1; SMN2MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230070613-A1 | PROTEIN TYROSINE KINASE 6 (PTK6) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-03-09 | — | — | US | disclosed |
| US-8759352-B2 | 1-(4-ureidobenzoyl)piperazine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-06-24 | — | — | US | disclosed |
| EP-2318368-B1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2013-10-16 | — | — | EP | disclosed |
| US-8357679-B2 | Hexafluoroisopropanol derivatives | MSD OSS B.V. (NL) | 2013-01-22 | — | — | US | disclosed |
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. ORGANON (NL) | 2012-01-19 | — | — | US | disclosed |
| EP-2297118-B1 | N- (1, 1, 1, 3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) BENZYL-N' -ARYLCARBONYLPIPERAZ INE DERIVATIVES AS LXR MODULATORS | ORGANON NV (NL) | 2011-10-05 | — | — | EP | disclosed |
| EP-2297118-A1 | N- (1, 1, 1, 3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) BENZYL-N' -ARYLCARBONYLPIPERAZ INE DERIVATIVES | N.V. Organon (NL) | 2011-03-23 | — | — | EP | disclosed |
| US-20100029621-A1 | HEXAFLUOROISOPROPANOL DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2010-02-04 | — | — | US | disclosed |
| WO-2009138438-A1 | N- (1, 1, 1, 3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) BENZYL-N' -ARYLCARBONYLPIPERAZ INE DERIVATIVES | N.V. ORGANON (NL) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230070613-A1 | PROTEIN TYROSINE KINASE 6 (PTK6) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | PTK6, NEK6, GRK6 | KMT2A 1941/4885MEN1 1801/4885HDAC1 2492/4885 |
| US-20100029621-A1 | HEXAFLUOROISOPROPANOL DERIVATIVES | FFAR2, FFAR3, FFAR1 | KMT2A 4742/4885MEN1 2373/4885HDAC1 2227/4885 |
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | NPC1, ABCB11, NPC1L1 | KMT2A 4136/4885MEN1 3167/4885HDAC1 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.